Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 8/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 2/20 | 0.48 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 4/20 | 0.46 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3428140 | 0.89 | PTGER4 (0.52) | PTGER4F2PLAUELANEMCL1 | |
| SCHEMBL1897336 | 0.86 | PTGER4 (0.59) | PTGER4F2PLAUELANECNR1 | |
| SCHEMBL24273650 | 0.85 | PTGER4 (0.61) | PTGER4F2PLAUELANEMCL1 | |
| SCHEMBL29459644 | 0.85 | PTGER4 (0.61) | PTGER4F2PLAUELANEMCL1 | |
| SCHEMBL1214430 | 0.84 | PTGER4 (0.62) | PTGER4F2PLAUELANECNR1 | |
| SCHEMBL2433523 | 0.84 | PTGER4 (0.68) | PTGER4F2PLAUELANECNR1 | |
| SCHEMBL19381384 | 0.83 | PTGER4 (0.58) | PTGER4F2PLAUELANEMCL1 | |
| SCHEMBL26204710 | 0.80 | ELANE (0.59) | PTGER4F2PLAUELANESMN1; SMN2 | |
| SCHEMBL6114223 | 0.78 | PTGER4 (0.57) | PTGER4CNR1F2RL3 | |
| SCHEMBL1107656 | 0.78 | PTGS2 (0.48) | PTGER4MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257340-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-12-08 | — | — | EP | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| WO-2009121623-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | CPT1B, SMN1; SMN2, GYS1 | PTGER4 3500/4885F2 3808/4885PLAU 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.